Eun Hye Oh

Eun Hye Oh

Auto-generated profile, based on publicly available information

Eun Hye Oh

Department of Gastroenterology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EOEun Hye Oh
Eun Hye Oh
KOKyunghwan Oh
Kyunghwan Oh
MHMinkyu Han
Minkyu Han
HSHyungil Seo
Hyungil Seo
KCKiju Chang
Kiju Chang
BYByong Duk Ye
Byong Duk Ye
Although early treatment of Crohn’s disease (CD) patients with anti-tumor necrosis factor (TNF) agents or immunomodulators (IMs) may improve long-term outcomes, especially those with poor prognostic factors, their effectiveness in Asians remains unclear. In this study, Korean patients with CD naïve to both intestinal surgery and intestinal complications, and with at least two risk factors for progression (diagnosis at age <40 years, systemic corticosteroid treatment <3 months after diagnosis, and perianal fistula at diagnosis) were retrospectively analyzed. Patients were classified into those who started anti-TNFs, or IMs but not anti-TNFs, within 2 years of diagnosis, and those who started anti-TNFs and/or IMs later. Their probabilities of intestinal surgery and intestinal complications were compared. A total of 670 patients were enrolled, 79 in the early anti-TNF, 286 in the early IM, and 305 in the late treatment group. Kaplan-Meier analysis with the log-rank test showed that from starting anti-TNFs/IMs, times to intestinal surgery (P < 0.001), stricturing complications (P = 0.002), and penetrating complications (P < 0.001) were significantly longer in the early anti-TNF/IM groups than in the late treatment group. Multivariate Cox regression analysis showed that, from starting anti-TNFs/IMs, late anti-TNF/IM treatment was independently associated with higher risks of intestinal surgery (adjusted hazard ratio [aHR] 2.321, 95% confidence interval [CI] 1.503–3.584, P < 0.001), behavioral progression (aHR 2.001, 95% CI 1.449–2.763, P < 0.001), stricturing complications (aHR 1.736, 95% CI 1.209–2.493, P = 0.003), and penetrating complications (aHR 3.315, 95% CI 2.094–5.249, P < 0.001) than early treatment. In conclusion, treatment of Asian CD patients having poor prognostic factors with anti-TNFs/IMs within 2 years of diagnosis is associated with better clinical outcomes than later treatment.

4 September 2019 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
ESEun Mi Song
Eun Mi Song
HLHo-Su Lee
Ho-Su Lee
YKYe-Jee Kim
Ye-Jee Kim
EOEun Hye Oh
Eun Hye Oh
NHNam Seok Ham
Nam Seok Ham
SYSuk-Kyun Yang
Suk-Kyun Yang

1 October 2021 in Gut and Liver
Verified
Journal Article
Open access
PDF file
JLJi Min Lee
Ji Min Lee
PTPO-NIEN TSAO
PO-NIEN TSAO
KLKang-Moon Lee
Kang-Moon Lee
BYByong Duk Ye
Byong Duk Ye
RMRen Mao
Ren Mao
KTKen Takeuchi
Ken Takeuchi
Ji Min Lee, Shu-Chen Wei, Kang-Moon Lee, Byong Duk Ye, Ren Mao, Hyun-Soo Kim, Soo Jung Park, Sang Hyoung Park, Eun Hye Oh, Jong Pil Im, Byung Ik Jang, Dae Bum Kim, and Ken Takeuchi. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl210081

6 September 2019 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
NHNam Seok Ham
Nam Seok Ham
JKJeongseok Kim
Jeongseok Kim
EOEun Hye Oh
Eun Hye Oh
SHSung Wook Hwang
Sung Wook Hwang
SPSang Hyoung Park
Sang Hyoung Park
JBJeong-Sik Byeon
Jeong-Sik Byeon

31 January 2023 in Intestinal Research
Verified
Journal Article
Open access
PDF file
SKSu Young Kim
Su Young Kim
MKMin Seob Kwak
Min Seob Kwak
SYSoon Man Yoon
Soon Man Yoon
YJYunho Jung
Yunho Jung
JKJong Wook Kim
Jong Wook Kim
KDKorean Association for the Study of Intestinal Diseases
Korean Association for the Study of Intestinal Diseases
Colonoscopic polypectomy is effective in decreasing the incidence and mortality of colorectal cancer (CRC). Premalignant polyps discovered during colonoscopy are associated with the risk of metachronous advanced neoplasia. Postpolypectomy surveillance is the most important method for managing advanced metachronous neoplasia. A more efficient and evidence-based guideline for postpolypectomy surveillance is required because of the limited medical resources and concerns regarding colonoscopy complications. In these consensus guidelines, an analytic approach was used to address all reliable evidence to interpret the predictors of CRC or advanced neoplasia during surveillance colonoscopy. The key recommendations state that the high-risk findings for metachronous CRC following polypectomy are as follows: adenoma ≥10 mm in size; 3 to 5 (or more) adenomas; tubulovillous or villous adenoma; adenoma containing high-grade dysplasia; traditional serrated adenoma; sessile serrated lesion containing any grade of dysplasia; serrated polyp of at least 10 mm in size; and 3 to 5 (or more) sessile serrated lesions. More studies are needed to fully comprehend the patients who are most likely to benefit from surveillance colonoscopy and the ideal surveillance interval to prevent metachronous CRC.

1 January 2022 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
KOKyunghwan Oh
Kyunghwan Oh
EOEun Hye Oh
Eun Hye Oh
SNSoo Min Noh
Soo Min Noh
SPSeong Ho Park
Seong Ho Park
NKNayoung Kim
Nayoung Kim
BYByong Duk Ye
Byong Duk Ye
INTRODUCTION: Although endoscopic healing (EH) is recommended as the therapeutic goal in patients with Crohn's disease (CD), combined EH and radiologic healing (RH) could be a more ideal therapeutic goal considering the transmural nature of CD. We compared the prognosis of patients with CD who achieved EH, RH, both EH and RH (deep healing; DH), or no healing under treatment with anti-tumor necrosis factor (TNF) agents. METHODS: We analyzed 392 patients with CD who received anti-TNF treatment for more than 1 year and evaluated with CT enterography or magnetic resonance enterography together with colonoscopy within 3 months between July 2017 and December 2018. Major outcomes (anti-TNF dose intensification, switch to other biologics, CD-related bowel resection, and hospitalization) were compared according to the EH and RH status. RESULTS: During the follow-up (median 18 months; interquartile range, 15–21), the DH group showed a better rate of major outcome-free survival compared with other groups (P < 0.001). In multivariable analysis, elevated C-reactive protein (adjusted hazard ratio [aHR], 2.166; 95% confidence interval [CI], 1.508–3.110; P < 0.001), EH-only (aHR, 3.903; 95% CI, 1.635–9.315; P = 0.002), RH-only (aHR, 3.843; 95% CI, 1.545–9.558; P = 0.004), and no healing (aHR, 8.844; 95% CI, 4.268–18.323; P < 0.001) were associated with increased risks of major outcomes. DISCUSSION: Patients with CD who achieved DH under anti-TNF therapy showed a better prognosis compared with those who only achieved EH. The possibility of DH being used as a new therapeutic target for patients with CD should be investigated in further studies.